Promising pill may halt vitiligo and bring back pigment
NCT ID NCT06327321
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also receive UVB light therapy. The main goal is to measure at least a 50% improvement in facial depigmentation using a special camera.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deucravacitinib
What this could lead to
If successful, this could offer a new oral treatment to stop vitiligo from spreading and help restore skin color.
What could go wrong
This is a mid-stage trial with only 128 participants, so results may not apply to everyone. Deucravacitinib also carries risks like infection or side effects seen in similar drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO, GENERALIZED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP, Henri Mondor
Paris, Creteil, France
-
CHU de Bordeaux
Bordeaux, Talence, 33000, France
-
CHU de Lille
Lille, France
-
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-Maritimes, 06200, France
-
HCL
Lyon, France